Pharmacopsychiatry 2004; 37: 120-125
DOI: 10.1055/s-2004-832665
General Concepts
© Georg Thieme Verlag KG Stuttgart · New York

Concepts on Neurological Disease Evolution

R. J. Seitz1
  • 1Department of Neurology, University Hospital Düsseldorf, Düsseldorf, Germany
Further Information

Publication History

Publication Date:
16 November 2004 (online)

Degenerative neurological diseases evolve progressively with an insidious onset, while relapsing neurological diseases may remit completely or result in progressive deficits. Since the affected systems can be assessed by clinical evaluation and ascribed to disease-specific pathology - today already in vivo using neuroimaging, the mechanisms underlying neurological disease manifestation can also be studied. For the most frequent neurological diseases with a relapsing clinical course, such as multiple sclerosis, brain infarction and epilepsy, it is shown that disease-specific aetiopathogenesis, lesion-specific pathophysiology and unspecific bystanders determine disease manifestation. Nevertheless, prediction of progression or relapse of a neurological disease is poor due to ill-defined relations of molecular genetic markers and disease evolution. Recent research on aetiopathogenesis and pathophysiology providing new perspectives for selective therapeutic interventions and relapse prevention is discussed.

References

  • 1 Albers G W, Caplan L R, Easton J D, Fayad P B, Mohr J P, Saver J L, Sherman D G. TIA Working Group. Transient ischemic attack-proposal for a new definition.  N Engl J Med. 2002;  347 1713-1716
  • 2 Antithrombotic trialists’ c ollaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-81
  • 3 Arnold S, Schlaug G, Niemann H, Ebner A, Lüders H, Witte O W, Seitz R J. Topography of interictal metabolic depressions in mesiotemporal lobe epilepsy.  Neurology. 1996;  46 1422-1430
  • 4 Bjartmar C, Trapp B D. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences.  Curr Opin Neurol. 2001;  14 271-278
  • 5 Barone F C, Feuerstein G Z. Inflammatory mediators and stroke: new opportunities for novel therapeutics.  J Cereb Blood Flow Metab. 1999;  19 819-834
  • 6 Bauer J, Elger C E. Medikamentöse antikonvulsive Therapie.  Nervenarzt. 1995;  66 403-411
  • 7 Bergamaschi R, Romani A, Tonietti S, Citterio A, Berzuini C, Cosi V. Usefulness of Bayesian graphical models for early prediction of disease progression in multiple sclerosis.  Neurol Sci. 2000;  21(Suppl 2) S819-823
  • 8 Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.  N Engl J Med. 2003;  349 139-145
  • 9 Bigio E H, Lipton A M, White CL 3 rd, Dickson D W, Hirano A. Frontotemporal and motor neurone degeneration with neurofilament inclusion bodies: additional evidence for overlap between FTD and ALS.  Neuropathol Appl Neurobiol. 2003;  29 239-253
  • 10 Binkofski F, Seitz R J, Hackländer T, Pawelec D, Mau J, Freund H -J. The recovery of motor functions following hemiparetic stroke: a clinical and MR-morphometric study.  Cerebrovasc Dis. 2001;  11 273-281
  • 11 Bladin C F, Alexandrov A V, Bellavance A, Bornstein N, Chambers B, Cote R, Lebrun L, Pirisi A, Norris J W. Seizures after stroke: a prospective multicenter study.  Arch Neurol. 2000;  57 1617-1622
  • 12 Bomprezzi R, Ringner M, Kim S, Bittner M L, Khan J, Chen Y, Elkahloun A, Yu A, Bielekova B, Meltzer P S, Martin R, McFarland H F, Trent J M. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease.  Hum Mol Genet. 2003;  12 2191-2199
  • 13 Bütefisch C M, Netz J, Wessling M, Seitz R J, Hömberg V. Remote changes in cortical excitability after stroke.  Brain. 2003;  126 470-481
  • 14 Chabriat H, Joutel A, Vahedi K, Iba-Zizen M T, Tournier-Lasserve E, Bousser M G. CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy).  J Mal Vasc. 1996;  21 277-282
  • 15 Chapman M G, Smith M, Hirsch N P. Status epilepticus.  Anaesthesia. 2001;  56 648-659
  • 16 Di Napoli M, Papa F, Villa Pini Stroke Data I nvestigators. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients.  Stroke. 2002;  33 1763-1771
  • 17 Fulton J C, Grossman R I, Mannon L J, Udupa J, Kolson D L. Familial multiple sclerosis: volumetric assessment in clinically symptomatic and asymptomatic individuals.  Mult Scler. 1999;  5 74-77
  • 18 Gershon A A, Dannon P N, Grunhaus L. Transcranial magnetic stimulation in the treatment of depression.  Am J Psychiatry. 2003;  160 835-845
  • 19 Gretarsdottir S, Sveinbjornsdottir S, Jonsson H H, Jakobsson F, Einarsdottir E, Agnarsson U, Shkolny D, Einarsson G, Gudjonsdottir H M, Valdimarsson E M, Einarsson O B, Thorgeirsson G, Hadzic R, Jonsdottir S, Reynisdottir S T, Bjarnadottir S M, Gudmundsdottir T, Gudlaugsdottir G J, Gill R, Lindpaintner K, Sainz J, Hannesson H H, Sigurdsson G T, Frigge M L, Kong A, Gudnason V, Stefansson K, Gulcher J R. Localization of a susceptibility gene for common forms of stroke to 5q12.  Am J Hum Genet. 2002;  70 593-603
  • 20 Hartung H P, Kieseier B C. Autoimmunity in the nervous system. In: Noseworthy (ed) Neurological Therapeutics: Principle and Practice. London; Martin Dunitz 2003: pp 1094-1106
  • 21 Helmstaedter C, Reuber M, Elger C C. Interaction of cognitive aging and memory deficits related to epilepsy surgery.  Ann Neurol. 2002;  52 89-94
  • 22 Jander S, Sitzer M, Schumann R, Schroeter M, Siebler M, Steinmetz H, Stoll G. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization.  Stroke. 1998;  29 1625-1630
  • 23 Jokeit H, Seitz R J, Markowitsch H J, Neumann N, Witte O W, Ebner A. Prefrontal asymmetric interictal glucose hypometabolism and cognitive impairment in patients with temporal lobe epilepsy.  Brain. 1997;  120 2283-2294
  • 24 Kanemoto K, Tsuji T, Kawasaki J. Reexamination of interictal psychoses based on DSM IV psychosis classification and international epilepsy classification.  Epilepsia. 2001;  42 98-103
  • 25 Kessler K R, Schnitzler A, Classen J, Benecke R. Reduced inhibition within primary motor cortex in patients with poststroke focal motor seizures.  Neurology. 2002;  59 1028-1033
  • 26 Kidwell C S, Saver J L, Mattiello J, Starkman S, Vinuela F, Duckwiler G. et al . Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging.  Ann Neurol. 2000;  47 462-469
  • 27 Kieseier B C, Hartung H P. Multiple paradigm shifts in multiple sclerosis.  Curr Opin Neurol. 2003;  16 247-252
  • 28 Lang A E, Lozano A M. Parkinson’s disease. First of two parts.  N Engl J Med. 1998;  339 1044-1053
  • 29 Lang A E, Lozano A M. Parkinson’s disease. Second of two parts.  N Engl J Med. 1998;  339 1130-1143
  • 30 La Spada A R, Paulson H L, Fischbeck K H. Trinucleotide repeat expansion in neurological disease.  Ann Neurol. 1994;  36 814-822
  • 31 Litt B, Echauz J. Prediction of epileptic seizures.  Lancet Neurol. 2002;  1 22-30
  • 32 Lozano A M, Dostrovsky J, Chen R, Ashby P. Deep brain stimulation for Parkinson’s disease: disrupting the disruption.  Lancet Neurol. 2002;  1 225-231
  • 33 Macdonald R L, Kapur J. Acute cellular alterations in the hippocampus after status epilepticus.  Epilepsia. 1999;  Suppl 1 S9-20
  • 34 Mesulam M M. Large-scale neurocognitive networks and distributed processing for attention, language, and memory.  Ann Neurol. 1990;  28 597-613
  • 35 Orozco Diaz G, Nodarse Fleites A, Cordoves Sagaz R, Auburger G. Autosomal dominant cerebellar ataxia: clinical analysis of 263 patients from a homogeneous population in Holguin, Cuba.  Neurology. 1990;  40 1369-1375
  • 36 Parsons M W, Barber P A, Chalk J, Darby D G, Rose S, Desmond P M, Gerraty R P, Tress B M, Wright P M, Donnan G A, Davis S M. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke.  Ann Neurol. 2002;  51 28-37
  • 37 Poser C M, Brinar V V. Epilepsy and multiple sclerosis.  Epilepsy Behav. 2003;  4 6-12
  • 38 Scheel H, Tomiuk S, Hofmann K. A common protein interaction domain links two recently identified epilepsy genes.  Hum Mol Genet. 2002;  11 1757-1762
  • 39 Kraemer M, Schormann T, Hagermann G, Bi Q, Witte O W, Seitz R J. (2004) Delayed shrinkage of the brain ischemic stroke: Preliminary Observations with Voxel-Guided Morphometry. J Neuroimaging 14: 265-272
  • 40 Seitz R J. Recovery of executive functions.  In: Handb. Neuropsychol, Boller F, Grafman J. (eds), Vol 11: Action and Cognition, Jeannerod M. (section ed.) Amsterdam; Elsevier 1997: pp 185-207
  • 41 Seitz R J, Azari N P. Postlesional neuroplasticity in man.  In: Plasticity and epilepsy. Stefan H, Andermann F, Shorvon S, Chauvel P. (eds) Adv Neurol 1999 81: 37-47
  • 42 Seitz R J, Binkofski F, Freund H -J. Prognosis after stroke.  In: Long-term effects of stroke. Bogousslavsky J. (ed.) New York; Marcel Dekker 2002: pp 105-147
  • 43 Sitzer M, Muller W, Siebler M, Hort W, Kniemeyer H W, Jancke L, Steinmetz H. Plaque ulceration and lumen thrombus are the main sources of cerebral microemboli in high-grade internal carotid artery stenosis.  Stroke. 1995;  28 1231-1233
  • 44 Squitieri F, Sabbadini G, Mandich P, Gellera C, Di Maria E, Bellone E, Castellotti B, Nargi E, de Grazia U, Frontali M, Novelletto A. Family and molecular data for a fine analysis of age at onset in Huntington disease.  Am J Med Genet. 2000;  95 366-373
  • 45 Stangel M, Hartung H P. Remyelinating strategies for the treatment of multiple sclerosis.  Prog Neurobiol. 2002;  68 361-376
  • 46 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995 333: 1581-1587
  • 47 Tzourio C. Vascular factors and cognition: toward a prevention of dementia.  J Hypertens Suppl. 2003;  21(Suppl. 5) S15-19
  • 48 Van Paesschen W, Connelly A, King M D, Jackson G D, Duncan J S. The spectrum of hippocampal sclerosis: a quantitative magnetic resonance imaging study.  Ann Neurol. 1997;  41 41-51
  • 49 Vonck K, Boon P, Achten E, DeReuck J, Caemaert J. Long-term amygdalohippocampal stimulation for refractory temporal lobe epilepsy.  Ann Neurol. 2002;  52 556-565
  • 50 Winterhalder M, Maiwald T, Voss H U, Aschenbrenner-Scheibe R, Timmer J, Schulze-Bonhage A. The seizure prediction characteristic: a general framework to assess and compare seizure prediction methods.  Epilepsy Behav. 2003;  4 318-325
  • 51 Yamakawa H, Jezova M, Ando H, Saavedra J M. Normalization of endothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1 receptor inhibition.  J Cereb Blood Flow Metab. 2003;  23 371-380

Prof. Dr. Rüdiger J. Seitz

Department of Neurology

University Hospital Düsseldorf

Moorenstraße 5

40225 Düsseldorf

Phone: +49 211 81 18974

Fax: +49 211 81 18485

Email: seitz@neurologie.uni-duesseldorf.de